Home > Publications Database > The akinetic crisis in Parkinson's disease - the upper end of a spectrum of subacute akinetic states. > print

001     272840
005     20241028164615.0
024 7 _ |a 10.1007/s00702-024-02817-8
|2 doi
024 7 _ |a pmid:39153024
|2 pmid
024 7 _ |a pmc:PMC11489269
|2 pmc
024 7 _ |a 0375-9245
|2 ISSN
024 7 _ |a 0022-3026
|2 ISSN
024 7 _ |a 0300-9564
|2 ISSN
024 7 _ |a 1435-1463
|2 ISSN
037 _ _ |a DZNE-2024-01258
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Pötter-Nerger, Monika
|0 0000-0001-7680-2147
|b 0
245 _ _ |a The akinetic crisis in Parkinson's disease - the upper end of a spectrum of subacute akinetic states.
260 _ _ |a Wien [u.a.]
|c 2024
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1730125694_21847
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The akinetic crisis is defined as an acute, potentially life-threatening, levodopa-resistant, severe aggravation of rigidity, severe akinesia, associated with high fever, disturbance of consciousness, dysphagia and autonomic symptoms often due to disruption of dopaminergic medication or infections. The akinetic crisis is a relatively rare event, however subacute mild-moderate motor symptom deterioration in Parkinson´s disease (PD) patients is a frequent cause of hospitalization. In this review, we propose that the akinetic crisis is the upper end of a continuous spectrum of acute akinetic states depending on the degree of the progressive levodopa-resistance. Clinical symptomatology, risk factors, and instrumental diagnostics as the DAT-SPECT reflecting a biomarker of levodopa-resistance will be discussed to evaluate the spectrum of akinetic states. Pathophysiological considerations about the potential role of proinflammatory cytokines on the progressive levodopa-resistance will be discussed and therapeutical, consensus-based guidelines will be presented.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Akinetic crisis
|2 Other
650 _ 7 |a Cytokines
|2 Other
650 _ 7 |a Neuroleptic malignant-like syndrome
|2 Other
650 _ 7 |a Parkinsonism-hyperpyrexia syndrome
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a Risk factors
|2 Other
650 _ 7 |a Spectrum acute akinetic states
|2 Other
650 _ 7 |a Therapy
|2 Other
650 _ 7 |a Antiparkinson Agents
|2 NLM Chemicals
650 _ 7 |a Levodopa
|0 46627O600J
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Parkinson Disease: drug therapy
|2 MeSH
650 _ 2 |a Parkinson Disease: complications
|2 MeSH
650 _ 2 |a Parkinson Disease: physiopathology
|2 MeSH
650 _ 2 |a Parkinson Disease: diagnosis
|2 MeSH
650 _ 2 |a Antiparkinson Agents: therapeutic use
|2 MeSH
650 _ 2 |a Levodopa
|2 MeSH
650 _ 2 |a Drug Resistance
|2 MeSH
700 1 _ |a Schrader, Christoph
|b 1
700 1 _ |a Jost, Wolfgang H
|b 2
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 3
|e Last author
|u dzne
773 _ _ |a 10.1007/s00702-024-02817-8
|g Vol. 131, no. 10, p. 1199 - 1207
|0 PERI:(DE-600)1481655-6
|n 10
|p 1199 - 1207
|t Journal of neural transmission
|v 131
|y 2024
|x 0375-9245
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/272840/files/DZNE-2024-01258.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/272840/files/DZNE-2024-01258.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:272840
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEURAL TRANSM : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-21
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
920 1 _ |0 I:(DE-2719)1110002
|k AG Höglinger
|l Translational Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110002
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21